Vir Biotechnology, Inc. VIR R2K
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -65.2% CAGR over 5 years.
- Earnings shrank at -61.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VIR Vir Biotechnology, Inc. R2K | 9.54 | - | $1.61B | - | -52.69% | -47.69% | -65.22% | -61.64% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.38M | 3.08M | - | - | 1.79M | 1.03M | -65.00K | 63.76M | -41.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 684.00K | 0 | 11.00K | -11.00K | 26.00K | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.59M | 1.79M | 1.02M | -54.00K | 63.73M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141.35M | 119.61M | 173.39M | 111.66M | 132.25M |
| Operating Income | - | - | -34.35M | - | -30.77M | -35.77M | -47.68M | - | -71.91M | -29.05M | -87.61M | - | -158.63M | 61.02M | -53.38M | 1.01B | -225.22M | 194.96M | -143.37M | -215.19M | -186.73M | -80.08M | -158.63M | - | - | -139.56M | -118.59M | -173.44M | -47.92M | -132.29M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -136.69M | -115.67M | -170.44M | -45.02M | -129.48M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -120.95M | -110.79M | -162.97M | -43.06M | -125.53M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00K | 170.00K | 168.00K | -137.00K | 170.00K |
| Net Income | -31.59M | -24.45M | -33.46M | -26.39M | -28.67M | -33.93M | -48.31M | -63.77M | -77.24M | -31.17M | -84.61M | -105.65M | -168.91M | 61.81M | 110.43M | 518.62M | -76.49M | 175.31M | -140.96M | -194.78M | -163.41M | -65.28M | -138.38M | - | - | -120.97M | -110.96M | -163.14M | -42.92M | -125.69M |
| Diluted EPS | - | - | - | - | -3.19 | -3.64 | -4.60 | -0.71 | -0.71 | -0.27 | -0.67 | -0.83 | -1.32 | 0.46 | 0.82 | 3.85 | -0.58 | 1.30 | -1.06 | -1.45 | -1.22 | -0.48 | -1.02 | - | - | -0.88 | -0.80 | -1.17 | -0.31 | -0.85 |
| R&D Expense | - | - | 29.84M | - | 25.87M | 29.80M | 39.86M | - | 64.98M | 79.65M | 70.68M | - | 134.87M | 86.13M | 98.67M | 90.23M | 115.08M | 114.17M | 157.64M | 168.08M | 145.03M | 100.12M | 105.11M | 195.18M | - | 118.64M | 97.51M | 151.46M | - | 108.92M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.58B | 39.49M | 63.71M | 66.52M |
| Cost of Revenue | - | - | - | - | - | 146.32M | 2.77M | 845.00K | 26.00K |
| Gross Profit | - | - | - | - | - | 1.43B | 36.73M | 62.87M | 66.49M |
| Operating Expenses | - | - | - | - | - | 601.09M | 707.48M | 615.04M | 546.00M |
| Operating Income | -81.50M | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -670.75M | -552.17M | -479.51M |
| EBITDA | - | - | - | - | - | 839.85M | -651.29M | -537.61M | -467.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | 754.28M | -628.19M | -523.11M | -437.77M |
| Tax Provision | - | - | - | - | - | 238.44M | -13.08M | -1.15M | 217.00K |
| Net Income | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.06M | -521.96M | -437.99M |
| Diluted EPS | - | - | -5.76 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 | -3.16 |
| R&D Expense | 62.51M | 100.23M | 148.47M | 302.41M | 448.01M | 474.65M | 579.72M | 506.50M | 455.97M |
Compounded Sales Growth
| 5 Years: | -65.22% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -61.64% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +93.12% |
| 6 Months: | +48.14% |
| 3 Months: | +4.95% |
| 1 Month: | -5.36% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 191.60M | 512.07M | 918.76M | - | 2.80B | 1.92B | 1.40B | 1.00B |
| Current Assets | - | - | - | - | - | - | 2.52B | 1.59B | 1.04B | 514.08M |
| Cash & Equivalents | - | 187.92M | 47.60M | 109.33M | 436.57M | - | 848.63M | 241.58M | 222.95M | 232.19M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 773.08M | 0 | - | - | - |
| Total Liabilities | - | - | 61.64M | 88.13M | 201.91M | - | 724.12M | 328.82M | 248.43M | 237.55M |
| Current Liabilities | - | - | 39.91M | 59.21M | 99.06M | - | 511.03M | 175.41M | 119.66M | 92.81M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 127.97M | 124.54M | 97.89M | 97.85M |
| Total Equity | -7.97M | -68.92M | -179.18M | 423.94M | 716.85M | - | 2.08B | 1.59B | 1.15B | 765.28M |
| Shares Outstanding | - | - | - | - | - | - | 133.24M | 134.78M | 136.96M | 139.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -66.38M | -94.10M | -129.63M | -190.94M | - | 1.66B | -778.78M | -446.35M | -391.78M |
| Investing Cash Flow | -29.99M | -60.44M | -256.16M | -9.86M | - | -1.19B | 164.63M | 499.37M | 310.37M |
| Financing Cash Flow | 271.18M | 24.98M | 449.24M | 529.47M | - | 34.76M | 7.48M | 4.39M | 3.79M |
| Capital Expenditure | -2.74M | -8.19M | -8.94M | -6.55M | - | -68.01M | -21.57M | -7.30M | -4.83M |
| Free Cash Flow | -69.12M | -102.29M | -138.57M | -197.49M | - | 1.60B | -800.36M | -453.65M | -396.61M |
| Net Change in Cash | - | - | - | - | - | 504.55M | -606.68M | 57.40M | -77.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 90.7% | 93.0% | 98.7% | 100.0% |
| Operating Margin % | - | - | - | - | - | 52.7% | -1,698.3% | -866.7% | -720.9% |
| Net Margin % | - | - | - | - | - | 32.6% | -1,557.4% | -819.2% | -658.4% |
| ROE % | 101.4% | 64.7% | -41.2% | -41.7% | - | 24.8% | -38.7% | -45.4% | -57.2% |
| ROCE % | - | -78.2% | -39.3% | -36.2% | - | 36.4% | -38.5% | -43.2% | -52.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.67% | 18.00M | $171.70M |
| 2 | Arch Venture Management, Llc | 7.66% | 12.92M | $123.22M |
| 3 | SB Investment Advisers (UK) LTD | 6.49% | 10.95M | $104.44M |
| 4 | Vanguard Portfolio Management LLC | 5.46% | 9.22M | $87.92M |
| 5 | GSK plc | 5.07% | 8.55M | $81.58M |
| 6 | State Street Corporation | 4.23% | 7.14M | $68.13M |
| 7 | Vanguard Capital Management LLC | 3.19% | 5.38M | $51.35M |
| 8 | Goldman Sachs Group Inc | 1.93% | 3.25M | $31.01M |
| 9 | Morgan Stanley | 1.69% | 2.85M | $27.23M |
| 10 | Adar1 Capital Management, LLC | 1.63% | 2.74M | $26.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VIR